0LOV Stock Chart & Stats
$7.24
$0.04(0.66%)
At close: 4:00 PM EDT
$7.24
$0.04(0.66%)
Day’s Range― - ―
52-Week Range$3.44 - $10.67
Previous CloseN/A
Volume3.17K
Average Volume (3M)5.41K
Market Cap
$673.79M
Enterprise Value$330.42
Total Cash (Recent Filing)$136.35M
Total Debt (Recent Filing)$84.33M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 11, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend Yield2.07%
Share Statistics
EPS (TTM)-2.46
Shares Outstanding90,563,440
10 Day Avg. Volume4,032
30 Day Avg. Volume5,407
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)9.35
Price to Sales (P/S)17.31
P/FCF Ratio-3.89
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.43Price Target Upside99.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.64
Revenue Forecast (FY)$116.45M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue And AdoptionThe rebound in product revenue and expanding adoption indicate that Verastem is building a commercial base rather than relying solely on development funding. More refills, new patient starts, and broader physician use can support recurring demand and strengthen the LGSOC franchise over the next several quarters.
Improved Liquidity And RunwayThe strengthened cash position gives Verastem more time to fund commercialization and clinical development without an immediate need for another capital raise. Extended runway improves strategic flexibility and increases the company’s ability to reach important clinical and commercial milestones.
Advancing Oncology PipelineRapid advancement of VS-7375 broadens Verastem’s potential beyond its current LGSOC franchise. Fast Track status, completed expansion enrollment, and registration-directed studies create multiple development pathways that could generate durable pipeline value if efficacy and safety are confirmed.
Bears Say
Persistent Losses And Cash BurnVerastem is not currently self-funding: substantial operating and free-cash-flow deficits require continued access to capital while the company scales revenue and advances trials. Persistent losses reduce financial resilience and could constrain investment or create additional funding needs before profitability is reached.
Leverage And Secured Financing DependenceMeaningful leverage limits financial flexibility while Verastem remains loss-making and cash-burning. The financing structure adds repayment obligations and asset security claims, making future capital allocation more constrained and increasing dependence on successful product revenue growth to support development and commercialization.
Tolerability And Competitive Execution RiskGastrointestinal adverse events and dose interruptions may reduce adherence, treatment duration, or real-world effectiveness as VS-7375 develops. These execution concerns are compounded by evolving competition and regulatory expectations, which could make differentiation and approval outcomes less predictable.
Verastem News
0LOV FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest share price was $3.44 and its highest was $10.66 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $673.79M.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Nov 11, 2026 which is in 51 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Aug 06, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.08.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 2.07%. See more information on Verastem dividends here
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.46.
How many shares outstanding does Verastem have?
Verastem has 90,563,440 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went up 10.939%.
Which hedge fund is a major shareholder of Verastem?
Currently, no hedge funds are holding shares in GB:0LOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verastem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.43 (99.29% Upside)
$14.43 (99.29% Upside)
Blogger Sentiment
Bullish
GB:0LOV Sentiment 71%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth $111.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Verastem
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
0LOV Company Deck
0LOV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum: commercial rebound with $25.1M in product revenue, strengthened liquidity via a $50M draw and $15M milestone (pro forma cash $201.4M), improved non-GAAP loss versus prior year, and rapid clinical progress for VS-7375 (enrollment completed in expansions, Fast Track for NSCLC, three Phase II studies initiated and an October data update anticipated). Notable risks remain — the company is still loss-making with high R&D spend, relies on financing to bridge to readouts, has limited prescription visibility, faces tolerability and dose-management operational challenges, and navigates a competitive/regulatory landscape. On balance, the material commercial and clinical achievements and improved financial cushion outweigh the outstanding challenges.View all GB:0LOV earnings summaries0LOV Stock 12 Month Forecast
Average Price Target
$14.43
▲(99.29% Upside)
Technical Analysis
Puma Biotechnology
―
CytomX Therapeutics
―
Arvinas Holding Company
―
Allogene Therapeutics
―
BridgeBio Oncology Therapeutics
―